NHS NEL
Demonstration Formulary
Demonstration Formulary
2 Cardiovascular system
02-12 Fibrates
Links
BCWB ICS CVD CLN Position Statement: Inclisiran (Leqvio). Approved 09/02/2022- CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
- CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
- CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
- CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
- CG181:Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
- Inclisiran dosing and administration guide
- Letter to accompany Inclisiran Medicines Optimisation pack October 2021
- Medicines Optimisation Pack for INCLISIRAN
- NHS Summary of National lipid management for primary and secondary prevention of cardiovascular disease
- NICE CG107: Hypertension in pregnancy: diagnosis and management
- NICE CG108: Chronic heart failure in adults: management
- NICE CG126: Stable angina: management
- NICE CG127: Hypertension in adults: diagnosis and management
- NICE CG180: Atrial fibrillation: management
- NICE CG181: Cardiovascular disease: risk assessment and reduction including lipid modification
- NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
- NICE NG185; Acute coronary syndromes
- NICE QS41: Familial Hypercholesterolaemia
- NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA805 :Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
- Patient Information: Changes to omega-3 fatty acids prescribing
- Patient Information: Changes to omega-3 fatty acids prescribing
- Procurement guide Inclisiran
- RCGP- BMA (December 2021): Information on the proposals for the prescription of inclisiran in primary care settings
- UKMI Q&A: Do statins cause alopecia?
- UKMI Q&A: Is there an interaction between erythromycin and statins?
- UKMI Q&A: Review of evidence dor dyslexia
- UKMI Q&A: What is the available evidence for the use of statins in patients with renal impairment?
- UKMIQ&A: Should patients on statins take Coenzyme Q10 supplementation to reduce the risk of statin-induced myopathy?
- West Midlands Familial Hypercholesterolaemia Service Index Patient Referral Pathway (Referring Clinician)